Akums Drugs & Pharmaceuticals Ltd.

₹470.3

-28.6 (-5.7%)

AKUMS Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 7,210 Cr

P/E Ratio21.29

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	491.34	Bearish
10-DMA	484.38	Bearish
20-DMA	481.75	Bearish
50-DMA	459.08	Bullish
100-DMA	449.1	Bullish
200-DMA	480.09	Bearish

Historical Performance

1 Year

-7.8%

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	41,182	41,782	36,548	36,719	27,226
Total Expenditure	36,575	40,552	33,608	37,636	24,315
Other Income	560	340	901	226	212
Operating Profit	5,166	1,570	3,841	-691	3,123
Interest	346	506	462	167	67
Depreciation	1,534	1,256	1,128	947	698
Profit Before Tax	3,453	-453	1,503	-1,932	1,719
Consolidated Net Profit	3,382	-40	949	-2,525	1,227
Adjusted EPS	22	---	7	-18	9

Compounded Sales Growth

10 Years:23

5 Years:11.3

3 Years:2.3

TTM:-0.3

Compounded Profit Growth

10 Years:50.7

5 Years:47.9

3 Years:-14.2

TTM:96.2

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:-7.8

Return on Equity

10 Years:4.8

5 Years:8.6

3 Years:6.6

last year:22.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	306	286	286	143	13
Total Reserves	30,164	6,809	6,886	6,077	8,835
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	-520	14,623	12,461	11,526	6,851
Other Current Liabilities	1,797	2,527	2,462	2,381	840
Short Term Borrowings	137	3,677	3,876	3,379	860
Total Liabilities	39,054	33,933	32,350	30,502	21,522
Capital Work in Progress	1,596	1,951	1,030	308	170
Long Term Loans & Advances	614	564	964	861	438
Currents Investments	---	---	---	---	190
Short Term Loans and Advances	2,150	1,694	1,393	1,450	990
Total Current Assets	22,746	19,408	18,789	18,641	11,574
Total Assets	39,054	33,933	32,350	30,502	21,522
Adjusted Book Value	199	50	50	43	62

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 21.29, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -40.9%, indicating poor shareholder returns.
The stock carries a beta of 1.1, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹5166 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹41182 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 926152

No. of Shares: 1969 (Approx)

Performance:-7.4%

P/L: ₹-73848

NIFTY Performance: 3.4%

1 day Top Gainers